LSIPR 50 2017: Carl Gordon—Realising great ideas


LSIPR  50 2017: Carl Gordon—Realising great ideas

Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.

One of the challenges facing healthcare venture capital firms is the pressure concerning drug pricing.

“We need companies to be able to charge a reasonable amount of money for the drugs because, if they can’t, we can’t make returns,” says Carl Gordon, founding partner and co-head of global private equity at OrbiMed.

“It’s easy to criticise pharmaceutical companies for charging a lot for their drugs, so that’s one issue we have to deal with,” he adds.

LSIPR 50 2017, venture capital firms, drug pricing, pharmaceutical companies, OrbiMed, Johnson & Johnson, AstraZeneca,pharmaceutical